The largest community of pharma leaders

Editor´s Pick

Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core...

Trump White House warns Americans against travel to South Korea, Italy

WASHINGTON (Reuters) - Travelers entering the United States from Italy, South Korea and Iran will face new restrictions as part of efforts to curtail...

ClinOne Offers Complimentary Support to Researchers Racing to Develop the Coronavirus or COVID-19 Vaccine

DENVER--(BUSINESS WIRE)--In December 2019, cases of Influenza, primarily Influenza A and Influenza B, were climbing dramatically within the United States. Globally, Influenza A was...

Regeneron likely to make coronavirus treatments available in few months

Medical workers in protective suits attend to patients at the Wuhan International Conference and Exhibition Center, which has been converted into a makeshift...

Recent Articles

PHARMACEUTICAL TECHNOLOGY: Is quantum computing pharma’s next big disruptor?

Quantum computing is the next frontier in the field of IT. One industry that is set to benefit significantly from the development of these...

BIO: Trump’s Revenge on Pharma

The Trump administration unveiled a new drug price control policy, drawing opposition from pharma manufacturers and pharmacy benefit managers. In unveiling a set of drug...

Global Genes Honors Leaders, Advocates, and Innovators in Rare Disease From Around the World at the 2020 RARE Champion of Hope Celebration

Global Genes, a leading rare disease patient advocacy organization, announces eight award recipients ⁠of diverse backgrounds and experiences through its annual Champion of Hope...

FDA to make emergency use authorization data public for COVID-19 vaccines

(Reuters) - The U.S. Food and Drug Administration said on Tuesday it would make public reviews of all data and information regarding the emergency...

U.S. FDA declines to approve Alkermes’ schizophrenia treatment

(Reuters) - The U.S. Food and Drug Administration did not approve Alkermes’ treatment for schizophrenia and bipolar disorder, the drugmaker said on Tuesday. Following a...

Moderna says UK deal will supply COVID-19 vaccine from March

(Reuters) - Moderna Inc MRNA.O confirmed on Tuesday it had agreed to supply its COVID-19 vaccine candidate, mRNA-1273, to the United Kingdom starting from the beginning...

Pfizer to start pilot delivery program for its COVID-19 vaccine in four U.S. states

(Reuters) - Pfizer Inc PFE.N has launched a pilot delivery program for its experimental COVID-19 vaccine in four U.S. states, as the U.S. drugmaker seeks to...

U.S. hospitals to restrict Lilly COVID-19 antibody treatment due to limited supply

(Reuters) - U.S. hospitals, weighing high demand and tight supplies, said they may limit use of a new Eli Lilly and Co LLY.N antibody drug to...

As pharmaceutical execs sell shares worth millions, questions arise

NEW YORK -- Pfizer, Moderna, Novavax: executives at several American laboratories developing COVID-19 vaccines have recently pocketed millions of dollars by selling shares in...

Coronavirus Vaccine: Moderna says its COVID-19 shot is nearly 95% effective

For the second time this month, there's promising news from a COVID-19 vaccine candidate: Moderna said Monday its shots provide strong protection, a dash...

Solace Therapeutics Announces that Premier Urology Medical Group Enrolls First Patient in US Pivotal Clinical Trial, Using New Office-Based Treatment for Female Stress Urinary...

POUGHKEEPSIE, N.Y.--(BUSINESS WIRE)--Premier Urology Medical Group has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in...

CytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative...

Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen’s Jelmyto® Effective January 1, 2021

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases,...

Lineage Cell Therapeutics Completes Patient Enrollment in Phase 1/2a Clinical Study of OpRegen® Cell Therapy for the Treatment of Dry Age-related Macular Degeneration

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for serious conditions, today...

Intensity Therapeutics Reports Favorable Data of INT230-6 from the Ongoing Phase 1/2 Study (IT-01/KEYNOTE A10) in Patients with Advanced Solid Tumors at SITC 2020...

WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of cancers,...